June 20 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Revive announces completion of rights offering for gross
proceeds of $844,693 to fund the clinical development of
Bucillamine for the treatment of Cystinuria
Source text for Eikon: ID:nCCNbWYNHy
Further company coverage: RVV.V